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Background: Generic substitution can have unintended 
consequences. In Germany, brand name to generic or 
generic to generic switching is mainly driven by rebate 
contracts. Frequent switching may raise concerns about 
bio- and therapeutic equivalence. Expected patient 
confusion may result in compromised medication 
adherence or new onset of other drug-related problems. 
Since 2008, pharmacists are allowed to deviate from 
rebate contracts by denying substitution due to 
pharmaceutical concerns on an individual basis. 
Objectives: To explore the frequency of documented 
pharmaceutical concerns in Germany between July 2011 
and December 2013 and to identify the medicines most 
frequently related to pharmaceutical concerns in 2013.  
Methods: We analyzed documented pharmaceutical 
concerns in all prescribed drugs at the expense of any 
statutory health insurance company requiring pharmacies’ 
generic substitution according to rebate contracts. 
Results: Since July 2011, the frequency of documented 
pharmaceutical concerns in relation to prescribed drug 
products with rebate contracts requiring substitution 
increased consistently and doubled between July 2011 
and July 2013. Overall in 2013, the trend of the two 
previous years continued and reached approximately 
1.5%. The most affected drugs/drug classes were thyroid 
hormones (in particular combinations with iodide; 15.9%) 
followed by ondansetron (12.5%), and levothyroxine 
(11.3%). For all drugs/drug classes under investigation, 
product-, patient- or disease-related aspects could be 
identified which are potential reasons to deny substitution 
and to document pharmaceutical concerns.  
Conclusions: Although there is no electronic recording of 
the specific reasons for pharmaceutical concerns in claims 
data, our analyses support the assumption that 
pharmacists make use of this instrument based on 
individual clinical decisions and as required by contract. 
Pharmaceutical concerns are, therefore, an important 
instrument for pharmacies to refuse generic substitution. 
They are considered to prevent compromised medication 
safety and to assure pharmacotherapy effectiveness in a 
generic substitution environment driven by low drug prizes 
above all. 
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INTRODUCTION 
In the German healthcare system, 90% of the 
population is covered by the statutory health 
insurance (SHI) system organized in 118 competing 
insurance funds as of 1 January 2016. Within the 
German SHI system, the generic market (generic 
prescribing, and generic substitution) has become 
highly relevant in recent years
1-3
 as around the 
world
4-7
, mainly in order to minimize costs.
1-3
  
Corresponding legislation in Germany initially 
allowed substitution with cheaper-priced drugs in 
the pharmacies only. Since 2007, it became 
mandatory for pharmacies to substitute the 
prescribed product for one where a rebate contract 
between the health insurance fund and a 
pharmaceutical manufacturer (Article 130a (8) 
Social Code Book V) has been negotiated (Gesetz 
zur Staerkung des Wettbewerbs in der Gesetzlichen 
Krankenversicherung (GKV-WSG 2007)). Rebate 
contracts are closed for any type of medicine 
requiring not only substituting an original by a 
generic. The contract may demand to exchange one 
generic by the other or even to exchange a 
prescribed generic for an original product.  
As the prescriber is usually unaware of the details of 
the rebate contracts, the patient is confronted with 
substitution at the time of dispensing in the 
pharmacy for the very first time. Product substitution 
can, however, be prevented by the prescriber via 
ticking the ‘aut idem’ box on the prescription form, 
which was used in approximately 19% of 
prescriptions in 2008.
8,9
 If the ‘aut idem’ box is 
ticked, the pharmacist must dispense the prescribed 
product. In other words, if the ‘aut idem’ box is not 
ticked and a rebate contract between the statutory 
health insurance fund and a pharmaceutical 
manufacturer has been closed, the pharmacy is 
obliged to dispense this product irrespective of the 
prescribed one. 
In 2008, the instrument of pharmaceutical concerns 
was introduced which allows pharmacies to deviate 
from rebate contracts denying substitution due to 
pharmaceutical concerns on an individual, case-by-
case basis and if there are justified reasons to do 
so. This is the case, for example, when – in spite of 
additional counseling of the patient – therapeutic 
efficacy including medication adherence or drug 
safety is expected to be compromised. Reasons 
may be related to suspected non-adherence, 
handling or other drug-related problems if 




Besides the properties of the specific drug product 
such as active ingredient, dosage form, 
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handling/administration, or name/appearance, 
among others, the patient itself including type of 
disease, disease state/severity, or level of health 
literacy may influence the feasibility and acceptance 
of substitution. Hence, the decision to document 
pharmaceutical concerns is based on the 
pharmacist’s professional judgment of the individual 
case. However, identifying frequent cases and 
finding out which drugs are most frequently 
concerned may be beneficial to identify common 
problems related to both rebate contracts and 
pharmaceutical concerns.  
In a setting of being obliged to fill a prescription 
according to rebate contracts, the new instrument of 
documenting pharmaceutical concerns on a 
prescription and, thereby, to deviate from rebate 
contracts is an important tool for pharmacists to 
fulfill their duties in ensuring medication safety and 
quality of care. To the best of our knowledge, this 
instrument has not been studied before. 
The aim of our study was to evaluate the frequency 
and potential reasons of pharmaceutical concerns. 
 
METHODS  
The database of the German Institute for Drug Use 
Evaluation (DAPI; www.dapi.de/en) comprises 
claims data of prescribed drugs dispensed at 
community pharmacies at the expense of SHI 
funds. This insurance system includes nearly 90% 
of the German population. The DAPI data cover 
claims data of more than 80% of all community 
pharmacies in Germany, without information on self-
medication (over-the-counter drugs, OTC), dosing, 
hospitalizations, diagnosis/indications or clinical 
data.  
Prescription data are linked to the ABDA database 
containing a complete inventory of German 
medicinal products and other items which are 
dispensed by pharmacies. A linkage is possible via 
a specific product code (“Pharmazentralnummer” 
(PZN)). The PZN is a unique identifier for medicinal 
products that precisely defines each drug package 
and provides e.g., information about the (brand) 
name, composition, active ingredient(s), strength, 
dosage form, package size (including standard 
sizes N1, N2 or N3), and pharmaceutical company. 
Since March 2011, technical documentation of 
pharmaceutical concerns and, hence, their 
quantification within pharmacy claims data were 
made possible by printing a specific code (2567024) 
on the prescription. This means that starting with 
this date it was possible to count prescriptions with 
documented pharmaceutical concerns. We 
continuously monitored documented pharmaceutical 
concerns for medicines dispensed at community 
pharmacies in Germany at the expense of the 
statutory health insurance funds, starting in July 
2011, by determining the frequency and type of 
products concerned utilizing the ATC code. We 
considered items prescribed only if the ‘aut idem’ 
box on the prescription was not ticked by the 
prescriber and generic substitution was possible 
and required by closed rebate contracts for this item 
by the specific SHI fund and a pharmaceutical 
manufacturer. These criteria were true for 
approximately 53% of the 611 million prescriptions 
Figure 1. All prescriptions, prescriptions where exchange for a product under rebate contract would have been 
possible, and prescriptions with documented pharmaceutical concerns in Germany between July 2011 and December 
2013. 
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of medicines to the expense of SHI funds in 
German community pharmacies in 2013. 
 
 RESULTS  
The overall number of documented pharmaceutical 
concerns is, related to the number of all 
prescriptions, very low, as can be seen in Figure 1. 
During 2011, there was no notable increase in the 
proportion of pharmaceutical concerns in relation to 
those prescriptions which were eligible for 
substitution due to at least one existing rebate 
contract and with the ‘aut idem’ box on the 
prescription not ticked. This situation changed in 
2012 when the frequency of documented 
pharmaceutical concerns in relation to prescribed 
items with rebate contracts requiring substitution 
increased consistently and doubled until July 2013. 
Overall in 2013, the trend of 2012 continued and 
reached approximately 1.5% (Figure 2). 
 Figure 3 shows the 20 drug substances most 
frequently related to pharmaceutical concerns in 
2013. Top drugs/drug classes (>10%) were thyroid 
hormones (in particular combinations with iodide; 
ATC code H03AA, 15.9% of 1.44 million 
prescriptions), ondansetron (A04AA01, 12.5% of 
0.14 million prescriptions), levothyroxine (H03AA01, 
11.3% of 8.45 Mio. prescriptions), phenprocoumon 
(B01AA04, 11.0% of 2.00 Mio. prescriptions), and 




Pharmaceutical concerns are an important 
instrument for pharmacists to refuse generic 
substitution required by law and closed rebate 
contracts between health insurance funds and 
pharmaceutical companies. Since July 2011, the 
frequency of documented pharmaceutical concerns 
in relation to prescribed drug products with rebate 
contracts requiring substitution increased 
consistently and doubled between July 2011 and 
July 2013. Overall in 2013, the trend of the two 
previous years continued and reached 
approximately 1.5%. 
When a pharmacist documents pharmaceutical 
concerns on a prescription, he is obliged to note the 
reason on the prescription form. These handwritten 
notes are not available electronically. Reasons for 
pharmaceutical concerns are diverse.
1,10,12
 They 
may result from circumstances of an individual 
person prescribed a concrete medicine. Hence, 
analyzing claims data does not allow exploration of 
individual reasons for pharmaceutical concerns 
documented. However, looking at the medicines 
frequently related to pharmaceutical concerns in 
detail, we found drugs with a narrow therapeutic 
index or a high potential for side effects (critical-
dose drugs), dosage forms difficult to handle or 
administer by the patient and/or care giver, or 
medicines for severe, psychiatric or neurological 
diseases.  
First, we identified drugs with a narrow therapeutic 
index or variable bioavailability requiring dose 
Figure 2. Prescriptions with documented pharmaceutical concerns (left y-axis) and proportion of prescriptions with 
documented pharmaceutical concerns of those prescriptions where exchange for a product under rebate contract 
would have been possible (right y-axis) in Germany between July 2011 and December 2013. 
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individualization such as thyroid hormones 
(levothyroxine, among others), the vitamin-K 
antagonist (VKA) phenprocoumon (used instead of 
warfarin in Germany), the thyreostatic thiamazole 
(see Figure 3 and online appendix Figure a), and 
levodopa. Especially VKAs bear the risk of 
thromboembolic events or increased bleeding risk 
when deviating from the individually defined 
dose.
1,11,13,14
 Even small dose changes of thyroid 
hormones such as levothyroxine may result in signs 
of clinical hyper- or hypothyreosis.
15
 Consequently, 
nearly all Summaries of Product Characteristics 
(SPC) of levothyroxine products require close 
monitoring including laboratory controls (TSH, fT4) 
when substituting.  
These aspects, among others, resulted in the 
decision of the Federal Joint Committee 
(Gemeinsame Bundesausschuss (G-BA)) as of 18 
September 2014 to include levothyroxine-sodium in 
tablets (both as mono therapy and as fixed-dosed 
combination containing potassium iodide) to the first 
list of medicines excluded from generic 
substitution.
16
 According to Article 129 (1a) 
sentence 2 Social Code Book V, the Federal Joint 
Committee is entitled to exclude specific drugs, 
especially those with a narrow therapeutic index, 
from substitution. 
 Secondly, pharmaceutical concerns were 
documented for specific dosage forms (see Figure 3 
and online appendix Figures b, and c): transdermal 
therapeutic systems (TTS; patches containing e.g. 
estradiol, fentanyl, buprenorphine), sustained-
/modified released dosage forms (e.g. opioids such 
as hydromorphone and morphine), parenteral 
dosage forms of high-risk substances (e.g. 
methotrexate) as well as inhalers (e.g. inhaled 
corticosteroids such as beclometasone). Since 
(metered-dose- or dry-powder-) inhalers are difficult 
to handle in general and inhalation technique is 
poor
17,18
, pharmaceutical concerns may (and shall) 
be used to prevent drug-related problems in asthma 




Further specific dosage forms frequently related to 
pharmaceutical concerns are orodispersible tablets 
containing, for example, the benzodiazepine 
lorazepam or the antiemetic ondansetron. In these 
cases, rebate contracts of two large health 
insurance funds, the local health insurance funds 
AOK (35% market share in 2013) and BARMER 
GEK, a substitutional social health insurance fund 
(13% market share in 2013), included coated tablets 
only. Substituting orodispersible tablets in patients 
with difficulties to swallow larger dosage forms or if 
a more rapid effect is required may cause problems. 
However, orodispersible dosage forms are not 
always the first choice as, among other reasons, 
these are usually moisture-sensitive and coated 
tablets are more stable if dispensed in weekly 
dosing-aids (dosettes).  
Another reason for pharmaceutical concerns can be 
related to different package sizes between the 
prescribed product and the product to be dispensed 
according to the rebate contract. This problem is 
probably the cause for pharmaceutical concerns 
documented on prescriptions for the cephalosporin 
antibiotics cefixime and cefpodoxime. For cefixime 
for example, these were mostly documented if the 
Figure 3. Drug substances most frequently related to pharmaceutical concerns in 2013. Percentages of prescribed items 
requiring substitution according to rebate contracts [detailed information is provided in online appendix Figures a to e]. 
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specific rebate contract required dispensing the 
standard package size N1 (smallest available on the 
market) containing five tablets whereas the 
dispensed, and probably prescribed, N1-product 
contained seven tablets. 
Apart from the specific medicine, the disease itself 
and resultant circumstances may be a reason to 
avoid substitution and to eventually document 
pharmaceutical concerns.
10
 This is imaginable in 
severe disease states when patients’ or care givers’ 
familiarity with the used medicine should not be 
compromised by substitution. This holds true e.g., 
for potent analgesics such as opioids 
(hydromorphone) and opiates (morphine) or in the 
case of neurological (antiepileptics
20
 or levodopa) or 
psychiatric illnesses (for example, the antipsychotic 
olanzapine).  
Concerns about compromised medication 
adherence may be another reason for pharmacists 
to document pharmaceutical concerns, for example 
when changes in the appearance of drug packages 
from one product to another can confuse the 
patient. Given the low medication adherence to 
long-term therapies (on average 50%, only)
21
, one 
would expect that the frequency of documented 
pharmaceutical concerns assuming a compromised 
medication adherence by dispensing a rebate 
product unknown to the patient should be much 
higher.
22-25
 However, the extent of this effect is not 
quantifiable as the literature on the impact of 
generic substitution on medication adherence is 
scarce. Changing from the ramipril originator to a 
generic did not significantly affect pharmacy refill 
compliance
26
 and changing from a brand-name 
atorvastatin to a generic product did not affect 
adherence of patients newly treated with 
atorvastatin.
27
 Hence, assuming compromised 
medication adherence when preventing generic 
substitution is not universally accepted as 
appropriate pharmaceutical concern. One example 
where a lack of medication adherence is assumed 
when changing between brands are oral 
contraceptives, which may be prescribed at the 




In summary and given the wide-spread problem of 
medication non-adherence
21,22,28-30
, the overall 
relatively low number of documented 
pharmaceutical concerns across Germany does not 
give reason to assume that pharmacists overuse 
this instrument, so far. 
We are not aware of significant changes in 
guidelines relevant to generic substitution during the 
analyzed periods. In addition, changes in the 
guidelines for German pharmacists in making use of 
the instrument of pharmaceutical concerns were not 
published. Therefore, we conclude that the changes 
in the proportion of pharmaceutical concerns for the 
various drugs, as depicted in online appendix 
Figures a) to e), are mainly driven by changes in 
rebate contracts. 
We abstained analyzing the economic impact of 
documented pharmaceutical concerns since key 
data for this analysis are not available: rebate prices 
are not disclosed to the public. The overall number 
of prescriptions with documented pharmaceutical 
concerns is very low and many prescriptions are not 
eligible to dispense a rebate instead of the 
prescribed product. Hence, the potential budget 




Pharmaceutical concerns are an important 
instrument for pharmacies to refuse generic 
substitution required by law and closed rebate 
contracts between health insurance funds and 
pharmaceutical companies. Although analyzing 
claims data does not allow exploration of the 
specific reasons for pharmaceutical concerns, our 
analyses of the data support the assumption that 
pharmacists make use of this instrument based on 
individual clinical decisions and as required by 
contract. Pharmaceutical concerns are considered 
to prevent compromised medication adherence and 
safety assuring pharmacotherapy effectiveness in a 
generic substitution environment driven by low drug 
prizes above all. 
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